In an EAN highlights session, Professor Christian Enzinger of the Medical University of Graz, Austria, selected key presentations to highlight regarding research in multiple sclerosis (MS).
His selection included a study by Comi et al (EPR-056) on the effects of treatment on work productivity. Data from the phase 3 CASTING study showed that work productivity scores improved over 2 years of treatment with ocrelizumab in patients with relapsing-remitting MS after failure of 1-2 prior disease-modifying therapies. Improvement in work productivity correlated with reduced MS symptom burden.